Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

Managing estradiol levels while using finasteride. Treatments discussed include Minoxidil, finasteride, and RU58841.

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

People are discussing the potential benefits and drawbacks of a new time-release oral minoxidil (VDPHL01) for hair loss, with considerations about its cost, efficacy, and side effects compared to current treatments like 2.5mg doses and topical applications. Some users express interest in trying it if it proves effective and affordable, while others are cautious due to potential side effects or are satisfied with their current regimen.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.